Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Yumanity Therapeutics (Nasdaq: YMTX) announced a stock option grant to a new employee for 30,000 shares at an exercise price of $10.88. The option vests over four years, with 25% vesting after one year and the remainder monthly thereafter. This option aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for the new hire. Yumanity is focused on developing therapies for neurodegenerative diseases, with its leading candidate YTX-7739 in Phase 1 trials for Parkinson's disease. The company is committed to innovating treatments for various neurodegenerative conditions.

Positive

• Granting stock options to attract talent can enhance company growth.
• Yumanity's drug discovery platform aims to address critical unmet needs in neurodegenerative diseases.
• YTX-7739's Phase 1 development indicates progress in the drug pipeline.

Negative

• Dependence on successful clinical trials poses significant risks for product candidates.
• Potential delays in clinical trials due to recruitment challenges and external factors like COVID-19.
• The risk that product candidates may not achieve desired efficacy could impact future financial performance.

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the grant to one new employee of a non-statutory stock option for the purchase of up to an aggregate of 30,000 shares of Yumanity’s common stock. The option will vest over four years, with 25 percent of the shares vesting on the first anniversary of the employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. The option has an exercise price of $10.88 per share, which is equal to the closing price of Yumanity’s common stock on September 1, 2021, the grant date for the stock option, has a ten-year term and is subject to the terms and conditions of the Yumanity Therapeutics, Inc. 2021 Inducement Plan and a stock option agreement covering the grant. The stock option was granted as an inducement material to the employee entering into employment with Yumanity Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4).

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Forward-Looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the potential therapeutic benefits of our prospective product candidates and results of preclinical studies, including YTX-7739, and the design, commencement, enrollment, and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, and the anticipated benefits of our drug discovery platform. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on Yumanity Therapeutics’ current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of our product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of Yumanity Therapeutics or our collaborators, the risk that Yumanity Therapeutics may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that Yumanity Therapeutics may not realize the intended benefits of its drug discovery platform, the risk that our product candidates will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving Yumanity Therapeutics’ product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Yumanity Therapeutics’ actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Yumanity Therapeutics’ most recent Annual or Quarterly Report, and other important factors in Yumanity Therapeutics’ subsequent filings with the Securities and Exchange Commission. Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D.
rflamm@burnsmc.com
(212) 213-0006

FAQ

What stock option grant was announced by Yumanity Therapeutics on September 9, 2021?

Yumanity Therapeutics announced a non-statutory stock option grant to a new employee for 30,000 shares at an exercise price of $10.88.

How does the stock option vest for Yumanity's new employee?

The stock option vests over four years, with 25% vesting on the first anniversary of the hire date and the remainder in equal monthly installments.

What is the significance of the stock option grant under Nasdaq Listing Rule 5635?

The stock option grant is made as an inducement for the new employee, in accordance with Nasdaq Listing Rule 5635(c)(4).

What is Yumanity Therapeutics' focus in drug development?

Yumanity Therapeutics focuses on developing disease-modifying therapies for neurodegenerative diseases.

What is the status of Yumanity's lead product candidate, YTX-7739?

YTX-7739 is currently in Phase 1 clinical development for Parkinson's disease.